SEATTLE, USA and CHIBA, Japan, July 17, 2025 (AGC Biologics) — AGC Biologics, a leading contract development and manufacturing organization, has entered a service agreement with Okayama University to advance a new therapeutic program.
The collaboration utilizes AGC Biologics’ global network, with cell line development in Seattle using its proprietary CHEF1™ expression platform, followed by process development at its cGMP-compliant mammalian manufacturing facility in Chiba, Japan, for clinical trials in 2026. The CHEF1™ platform has a proven track record, supporting over 55 molecules and five commercial products. Susumu Zen-in, General Manager of AGC Biologics’ Chiba facility, emphasized the project’s seamless integration of global expertise to serve academic institutions. This partnership highlights AGC Biologics’ commitment to supporting research institutions in developing innovative therapies.
Read the full article on agcbio.com
Share this page on social